PDCD1 and neoplasm: Additionally, synergized with anti-PD-1 and osimertinib, MSA-2 could enhance the anti-tumor effect and reverse the resistance of this therapy (Pan et al., 2020; Lin et al., 2023; Li et al., 2024; Yi et al., 2022).